PubMed Health⌕ Search

PubMed · 10235502

Small cell carcinocythemia.

Abstract

Tumor cells circulate in the blood, but it is unusual to find cancer cells on a routine peripheral smear. The term carcinocythemia is used to describe this phenomenon. Four patients have been reported previously with small cell lung cancer and carcinocythemia. A fifth case is described in this article. These patients presented with advanced disease and had generalized lymphadenopathy and liver involvement; 3 had splenic metastases. All of these patients experienced rapid clinical deterioration. Death occurred 3 days to 2 weeks from the time carcinocythemia was detected. The presence of small cell carcinocythemia can be one of the manifestations of end-stage disease and is associated with an extremely poor prognosis.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

C C Sile, D J Perry, L Nam. 1999. Small cell carcinocythemia.. https://doi.org/10.5858/1999-123-0426-scc

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Safety of topotecan in the treatment of recurrent small-cell lung cancer and ovarian cancer.

The topoisomerase I inhibitor, topotecan, is approved for the treatment of recurrent small-cell lung cancer (SCLC) and ovarian cancer (OC). Patients with recurrent SCLC and OC typically experience multiple relapses and receive multiple rounds of chemotherapy. In these settings, disease stabilisation is considered a treatment benefit, and quality-of-life effects and cumulative toxicities of treatments should be considered. Many patients with recurrent cancer may be predisposed to treatment-related adverse events because of advanced age, renal impairment or extensive prior therapy. The standard regimen of topotecan, 1.5 mg/m(2) on days 1-5 of a 21-day cycle, has generally mild nonhaematological toxicity and a well-defined haematological toxicity profile characterised by reversible and noncumulative neutropenia. Alternative regimens may lower the incidence of haematological toxicities and maintain antitumour efficacy. Topotecan may provide physicians with a versatile therapeutic option for the treatment of patients with relapsed SCLC or OC.

Carcinoma, Small Cell↗